Publications
Detailed Information
Efficacy and Safety of Low-Dose Cyclosporine Relative to Immunomodulatory Drugs Used in Atopic Dermatitis: A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyunghoon | - |
dc.contributor.author | Kim, Mina | - |
dc.contributor.author | Rhee, EunHee | - |
dc.contributor.author | Lee, Mi-Hee | - |
dc.contributor.author | Yang, Hyeon-Jong | - |
dc.contributor.author | Park, Suyeon | - |
dc.contributor.author | Kim, Hwan Soo | - |
dc.date.accessioned | 2024-05-13T07:32:27Z | - |
dc.date.available | 2024-05-13T07:32:27Z | - |
dc.date.created | 2023-04-07 | - |
dc.date.created | 2023-04-07 | - |
dc.date.issued | 2023-02 | - |
dc.identifier.citation | Journal of Clinical Medicine, Vol.12 No.4, p. 12041390 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://hdl.handle.net/10371/201597 | - |
dc.description.abstract | Cyclosporine A (CsA) is effective in treating moderate-to-severe atopic dermatitis (AD). This systematic review and meta-analysis aimed to summarize the effectiveness and safety of low-dose (<4 mg/kg) versus high-dose (>= 4 mg/kg) CsA and other systemic immunomodulatory agents in patients with AD. Five randomized controlled trials met the inclusion criteria. The meta-analysis included 159 patients with moderate-to-severe AD who were randomized to receive low-dose CsA, and 165 patients randomized to receive high-dose CsA and other systemic immunomodulatory agents. We found that low-dose CsA was not inferior to high-dose CsA and other systemic immunomodulatory agents in reducing AD symptoms [standard mean difference (SMD) -1.62, 95% confidence interval (CI) -6.47; 3.23]. High-dose CsA and other systemic immunomodulatory agents showed a significantly lower incidence of adverse events [incidence rate ratio (IRR) 0.72, 95% CI 0.56; 0.93], however, after sensitivity analysis, there was no difference between the two groups except for one study (IRR 0.76, 95% CI 0.54; 1.07). Regarding serious adverse events requiring discontinuation of treatment, we observed no significant differences between low-dose CsA and other systemic immunomodulatory agents (IRR 1.83, 95% CI 0.62; 5.41). Our study may justify the use of low-dose CsA rather than high-dose CsA and other systemic immunomodulatory agents in moderate-to-severe AD. | - |
dc.language | 영어 | - |
dc.publisher | MDPI AG | - |
dc.title | Efficacy and Safety of Low-Dose Cyclosporine Relative to Immunomodulatory Drugs Used in Atopic Dermatitis: A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/jcm12041390 | - |
dc.citation.journaltitle | Journal of Clinical Medicine | - |
dc.identifier.wosid | 000944983000001 | - |
dc.identifier.scopusid | 2-s2.0-85148937130 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 12041390 | - |
dc.citation.volume | 12 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Kyunghoon | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | LONG-TERM TREATMENT | - |
dc.subject.keywordPlus | ECZEMA | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | ADULTS | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | PREGNANCY | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordAuthor | atopic dermatitis | - |
dc.subject.keywordAuthor | cyclosporine A | - |
dc.subject.keywordAuthor | efficacy | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.